# NewLimit

**Source:** https://www.startuphub.ai/startups/newlimit
**Profile type:** Startup

> NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells.

## About

NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a "lab in a loop" system where AI models predict and experiments validate therapeutic candidates.

## Key facts

- **Slug:** newlimit
- **Website:** https://www.newlimit.com/
- **Location:** San Francisco Bay Area, USA
- **Founded:** 2022-01-01
- **Operating status:** Active
- **Total funding:** $215M
- **Sectors / tags:** Biotech, Longevity, Epigenetics, Drug Discovery, Machine Learning
- **Social:**
  - Twitter: https://twitter.com/newlimit

## StartupHub.ai scores

- **Ahrefs DR:** 44/100
- **Agent Readiness:** F (33/100)
- **Site Speed:** 55/100
- **Data Trust:** 63/100

## Funding rounds

| Date | Round | Amount | Lead investors |
| --- | --- | --- | --- |
| 20 Oct 2025 | [Series B Extension](https://www.startuphub.ai/investment_rounds/newlimit-series-b-extension-2025) | $45M | - |
| 6 May 2025 | [Series B](https://www.startuphub.ai/investment_rounds/newlimit-series-b-2025) | $130M | [Kleiner Perkins](https://www.startuphub.ai/investors/kleiner-perkins) |
| 8 May 2023 | [Series A](https://www.startuphub.ai/investment_rounds/newlimit-series-a-2023) | $40M | [Founders Fund](https://www.startuphub.ai/investors/founders-fund) |

## Tech stack

Detected on newlimit.com, last scanned 2026-10-21.

- **Frontend:** Tailwind CSS
- **CMS / Builders:** Webflow
- **CDN:** Cloudflare
- **Email provider:** Google Workspace
- **Email marketing:** Substack

## JSON-LD

Structured data aligned with this page's `<script type="application/ld+json">` (included when the profile is server-rendered).

```json
{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.startuphub.ai"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Startups",
          "item": "https://www.startuphub.ai/startups"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "NewLimit",
          "item": "https://www.startuphub.ai/startups/newlimit"
        }
      ]
    },
    {
      "@type": "ProfilePage",
      "@id": "https://www.startuphub.ai/startups/newlimit#webpage",
      "url": "https://www.startuphub.ai/startups/newlimit",
      "name": "NewLimit - AI Startup Profile | StartupHub.ai",
      "description": "This is the StartupHub.ai profile of NewLimit. NewLimit is a startup founded in 2022, operating in Biotech and Longevity. NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells. Headquartered in San Francisco Bay Area, USA.",
      "dateModified": "2026-10-31T09:49:43.976Z",
      "mainEntity": {
        "@type": "Organization",
        "@id": "https://www.startuphub.ai/startups/newlimit#organization"
      }
    },
    {
      "@type": "Organization",
      "@id": "https://www.startuphub.ai/startups/newlimit#organization",
      "name": "NewLimit",
      "url": "https://www.newlimit.com/",
      "logo": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/befc2311-696e-4af1-8dfa-724ee36936da-square.webp",
      "image": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/befc2311-696e-4af1-8dfa-724ee36936da-square.webp",
      "description": "NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a \"lab in a loop\" system where AI models predict and experiments validate therapeutic candidates.",
      "sameAs": [
        "https://twitter.com/newlimit"
      ],
      "foundingDate": "2022-01-01",
      "address": {
        "@type": "PostalAddress",
        "addressLocality": "San Francisco Bay Area",
        "addressCountry": "US"
      },
      "knowsAbout": [
        "Biotech",
        "Longevity",
        "Epigenetics",
        "Drug Discovery",
        "Machine Learning"
      ]
    }
  ]
}
```